𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: A multicenter study

✍ Scribed by Sagnelli Evangelista; Imparato Michele; Coppola Nicola; Pisapia Raffaella; Sagnelli Caterina; Messina Vincenzo; Piai Guido; Stanzione Maria; Bruno Marika; Moggio Giovanni; Caprio Nunzio; Pasquale Giuseppe; Del Vecchio Blanco Camillo


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
88 KB
Volume
80
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Occult hepatitis B virus (HBV) infection in patients with chronic hepatitis C has been found associated with severe liver damage, low response to interferon treatment and increased risk of developing HCC. However, doubts remain on its clinical impact and the sensitivity and specificity of its detection. HBV‐DNA was sought by PCR in plasma, peripheral blood mononuclear cells (PBMCs) and liver compartments of 89 patients with biopsy proven chronic hepatitis C, using sets of primers for core (“c”), surface (“s”), and x (“x”) regions of HBV genome. Occult HBV infection was defined by the presence of HBV‐DNA in at least two different PCRs in at least one compartment. Occult HBV infection was detected in 37 (41.6%) of the 89 patients investigated. It was more frequent (80.8%) in 26 anti‐ HBs negative/anti‐HBc positive patients than in 18 anti‐HBs/anti‐HBc positive (61.1%, P < 0.01) and 45 anti‐HBs/anti‐HBc negative (11.1%, P < 0.0001), and more frequently in liver (91.9%) than in PBMCs (62.2%) and plasma (32.4%). No association was found between occult HBV infection and the degree of liver necroinflammation and fibrosis. However, considering the 52 patients without occult HBV infection, 51.4% of 35 patients with genotype 1 and 5.9% of 17 with genotype non‐1 showed severe fibrosis (P = 0.003); patients with occult HBV infection did not show such difference. Instead of seeking occult HBV infection in patients with chronic hepatitis C, both anti‐HBs negative/anti‐HBc positive and anti‐HBs positive/anti‐HBc positive, in plasma alone, more reliable information can also be obtained from the liver tissue and PBMCs. J. Med. Virol. 80:1547–1553, 2008. © 2008 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Prevalence and impact of occult hepatiti
✍ Marion Levast; Sylvie Larrat; Marie-Ange Thelu; Sandrine Nicod; Agnès Plages; Al 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

## Abstract The prevalence of occult hepatitis B, defined by absence of HBsAg and HBV DNA, ranges widely in patients with hepatitis C. This may influence the treatment of hepatitis C and the severity of liver disease. Sensitive and specific real‐time PCR techniques are available commercially and ca

Distribution of hepatitis B virus in the
✍ Elena Rodríguez-Iñigo; Luisa Mariscal; Javier Bartolomé; Inmaculada Castillo; Cr 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 487 KB 👁 2 views

## Abstract Although occult hepatitis B virus (HBV) infection (HBV‐DNA in serum in the absence of hepatitis B surface antigen [HBsAg]) is common in chronic hepatitis C, its characteristics are not well known. In this work, the presence of HBV‐DNA (by polymerase chain reaction; PCR) and its distribu

Sequence analysis of pre-S/surface and p
✍ Jia-Horng Kao; Pei-Jer Chen; Ming-Yang Lai; Ding-Shinn Chen 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

Although occult hepatitis B virus (HBV) infection in individuals without detectable hepatitis B surface antigen (HBsAg) may occur and has been reported to be common in patients with chronic hepatitis C, the related molecular mechanisms remain unknown. With the polymerase chain reaction, serum HBV DN

Efficacy of entecavir in chronic hepatit
✍ I-Chin Wu; Ching-Lung Lai; Steven-Huy Bui Han; Kwang-Hyup Han; Stuart C. Gordon; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 1 views

Current guidelines for management of chronic hepatitis B recommend treatment for patients presenting with elevated hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) >2 x upper limit of normal (ULN) or histological evidence of liver disease. Retrospective analyses have demonstrated that